Compound · clinical trials

Livmoniplimab clinical trials

Also listed in trial records as ABBV-151

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 5 trials in our USA, France, Spain, Japan, Taiwan, South Korea, Israel, China, Italy, Poland, Canada, Belgium, Australia, Germany, Netherlands and Turkey registers that name Livmoniplimab as an intervention. Synced 9 Nov 2026

5Current trials

0Recruiting now

1Lead sponsor

16Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

Livmoniplimab is named as an intervention in 5 current clinical trials in our USA, France, Spain, Japan, Taiwan, South Korea, Israel, China, Italy, Poland, Canada, Belgium, Australia, Germany, Netherlands and Turkey registers. None are recruiting at the moment. The most common phase is Phase 2. The lead sponsor is AbbVie. The most-studied condition is Hepatocellular Carcinoma.

How Livmoniplimab works

All drug targets →

Binds LRRC32 Primary target
Target: LRRC32 leucine rich repeat containing 32
Guide to Pharmacology only

Diseases it has been tested for in clinical trials, by furthest phase

Hepatocellular carcinomaPhase 2/3
Non-small cell lung carcinomaPhase 2/3
Urothelial carcinomaPhase 2

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314989, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 11762, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Livmoniplimab

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Active, closed5100%

Trials by phase

Phase 2240%
Phase 2/3240%
Phase 1120%

Clinical trials of Livmoniplimab

5 trials

Study	Phase	Status	Lead sponsor	Registers
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) NCT06109272 · Hepatocellular Carcinoma	Phase 2/3	Active, closed	AbbVie	USA, China, France, Spain, Italy, Taiwan
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) NCT06236438 · Non-Small Cell Lung Cancer	Phase 2/3	Active, closed	AbbVie	USA, France, Spain, Netherlands, Belgium, Turkey, Japan, Taiwan, Australia, Israel
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) NCT05822752 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Active, closed	AbbVie	USA, China, France, Spain, Italy, Japan, South Korea, Taiwan
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) NCT06632951 · Urothelial Carcinoma	Phase 2	Active, closed	AbbVie	USA, France, Spain, Poland, Canada, Japan, South Korea, Israel
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors NCT03821935 · Advanced Solid Tumors Cancer	Phase 1	Active, closed	AbbVie	USA, China, Germany, France, Spain, Italy, Belgium, Poland, Canada, Japan, South Korea, Taiwan, Australia, Israel

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Livmoniplimab

4 conditions

Hepatocellular Carcinoma2 Urothelial Carcinoma1Advanced Solid Tumors Cancer1Non-Small Cell Lung Cancer1

By country register

Register	Trials	Recruiting
Clinical trials in USA	5	0
Clinical trials in France	5	0
Clinical trials in Spain	5	0
Clinical trials in Japan	4	0
Clinical trials in Taiwan	4	0
Clinical trials in South Korea	3	0
Clinical trials in Israel	3	0
Clinical trials in China	3	0
Clinical trials in Italy	3	0
Clinical trials in Poland	2	0
Clinical trials in Canada	2	0
Clinical trials in Belgium	2	0
Clinical trials in Australia	2	0
Clinical trials in Germany	1	0
Clinical trials in Netherlands	1	0
Clinical trials in Turkey	1	0

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Livmoniplimab trials

How many clinical trials are testing Livmoniplimab?

5 current trials in our USA, France, Spain, Japan, Taiwan, South Korea, Israel, China, Italy, Poland, Canada, Belgium, Australia, Germany, Netherlands and Turkey registers name Livmoniplimab (also registered as ABBV-151) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Livmoniplimab trials recruiting patients?

Not at the moment. None of the 5 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.

Who sponsors Livmoniplimab clinical trials?

The lead sponsor is AbbVie. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Livmoniplimab works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Livmoniplimab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Livmoniplimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.